Free Trial

Oculis (OCS) Stock Forecast & Price Target

$11.72
0.00 (0.00%)
(As of 07/19/2024 ET)

Oculis - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 6 Wall Street analysts who have issued ratings for Oculis in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 6 have given a buy rating for OCS.

Consensus Price Target

$30.17
157.39% Upside
High Forecast$37.00
Average Forecast$30.17
Low Forecast$20.00

According to the 6 analysts' twelve-month price targets for Oculis, the average price target is $30.17. The highest price target for OCS is $37.00, while the lowest price target for OCS is $20.00. The average price target represents a forecasted upside of 157.39% from the current price of $11.72.

TypeCurrent Forecast
7/21/23 to 7/20/24
1 Month Ago
6/21/23 to 6/20/24
3 Months Ago
4/22/23 to 4/21/24
1 Year Ago
7/21/22 to 7/21/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
9 Buy rating(s)
7 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$30.17$30.17$29.29$25.00
Forecasted Upside157.39% Upside154.36% Upside146.60% Upside126.81% Upside
Get Oculis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter.

OCS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OCS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Oculis Stock vs. The Competition

TypeOculisMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside157.39% Upside1,426.46% Upside10.03% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/11/2024Chardan Capital
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$30.00 ➝ $30.00+151.05%
6/11/2024HC Wainwright
3 of 5 stars
 Boost TargetBuy ➝ Buy$28.00 ➝ $30.00+150.00%
6/11/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$35.00 ➝ $37.00+208.33%
6/11/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$21.00 ➝ $20.00+66.67%
3/6/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$29.00+138.88%
10/4/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$35.00+216.17%
6/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Goodman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
6/12/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform
5/10/2023Pareto Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$23.00+115.76%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:02 AM ET.

OCS Forecast - Frequently Asked Questions

What is Oculis' forecast for 2024?

According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Oculis is $30.17, with a high forecast of $37.00 and a low forecast of $20.00.

Should I buy or sell Oculis stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Oculis in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" OCS shares.

Does Oculis's stock price have much upside?

According to analysts, Oculis's stock has a predicted upside of 154.36% based on their 12-month stock forecasts.

What analysts cover Oculis?

Oculis has been rated by research analysts at Bank of America, Chardan Capital, HC Wainwright, and Robert W. Baird in the past 90 days.

Do Wall Street analysts like Oculis more than its competitors?

Analysts like Oculis more than other "medical" companies. The consensus rating for Oculis is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how OCS compares to other companies.


This page (NASDAQ:OCS) was last updated on 7/20/2024 by MarketBeat.com Staff

From Our Partners